Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Arix to Present at the Jefferies Virtual London Healthcare Conference


Arix Bioscience PLC (ARIX)
Arix to Present at the Jefferies Virtual London Healthcare Conference

12-Nov-2020 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Arix Bioscience plc

 

Arix to Present at the Jefferies Virtual London Healthcare Conference

 

LONDON, 12 November 2020: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing and building breakthrough biotech companies, today announces that Dr. Naseem Amin, Executive Chairman, is scheduled to participate in an analyst led fireside chat at the Jefferies Virtual London Healthcare Conference on Tuesday, 17 November 2020, at 10:35am GMT.

 

A live webcast of the fireside chat will be available on the investor relations section of Arix's website at https://arixbioscience.com/investor-relations/events-presentations. After the conference, an archived replay will be available on the company's website at the same address.

 

[ENDS]

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

 

Optimum Strategic Communications

Supriya Mathur, Shabnam Bashir, Manel Mateus

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

 

For more information please visit: www.arixbioscience.com



ISIN: GB00BD045071
Category Code: MSCM
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 87702
EQS News ID: 1147540

 
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1147540&application_name=news&site_id=sharewise
Like: 0
Share
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Comments